Last updated: February 27, 2026
What is NDC 00143-9754?
NDC 00143-9754 is the National Drug Code designation for Lumacaftor/Ivacaftor combination, marketed as Orkambi. Approved by the U.S. Food and Drug Administration (FDA) in 2015, it targets cystic fibrosis (CF) patients with specific mutations, primarily the F508del mutation.
Market Size and Demand Dynamics
Cystic Fibrosis Population
- Estimated CF patients in the U.S.: approximately 35,000.
- Patients eligible for Orkambi: around 40% of CF population, roughly 14,000.
- Global CF population: approximately 100,000, with Europe and Canada representing substantial markets.
Prescribing Trends
- Steady growth in prescriptions since approval, influenced by increased diagnosis rates and expanding clinical guidelines.
- Prescription volume in the U.S.: approximately 2,500-3,000 units per quarter in 2022.
- Market penetration remains limited by price, alternative therapies, and insurance coverage.
Competitive Landscape
Key Competitors
- Kalydeco (ivacaftor) — targets a subset of CF mutations.
- Symdeko (tezacaftor/ivacaftor) — alternative with broader mutation coverage.
- Trikafta (elexacaftor/tezacaftor/ivacaftor) — approved in 2019, capturing the largest market share.
Market Share Shifts
- Trikafta holds approximately 75% of the CF drug market.
- Orkambi represents about 15-20%, with the remainder divided among other therapies.
- The trend indicates increasing adoption of triple-combination therapies over mono- or bi-therapy options.
Pricing History and Current Price
Historical Pricing
- 2015 launch price: approximately $259,000 annually per patient.
- Price adjustments: increased by around 4-6% annually, aligning with inflation and market factors.
Current Price Projections
| Year |
Estimated Annual Price (USD) |
Notes |
| 2023 |
$270,000 - $275,000 |
Slight increases due to inflation and pricing strategies |
| 2024 |
$275,000 - $280,000 |
Potential for price stabilization or slight dip due to competition |
| 2025 |
$280,000 - $285,000 |
Market pressures could influence price adjustments |
Factors Influencing Future Pricing
- Introduction of biosimilars or generic options if patent exclusivity ends.
- Competitive pressures from Trikafta and emerging therapies.
- Payer negotiations and value-based pricing models.
- Manufacturing costs and inflation.
Regulatory and Patent Considerations
Patent Status
- Original patents expired or nearing expiry in 2024-2025.
- Extended exclusivity through secondary patents or formulations could delay generic entry until 2030.
Regulatory Trends
- Ongoing FDA reviews for expanded indications.
- Potential approvals for pediatric populations, increasing market size.
Future Market and Price Trends
Market Growth Drivers
- Expansion into pediatric markets.
- Broader mutation coverage with new formulations.
- Increased diagnosis rates driven by newborn screening programs.
Impact on Pricing
- Price reductions likely with increased competition.
- Price stabilization or growth if regulatory exclusivity persists.
- Payer negotiations may lead to discounts or value-based agreements.
Summary of Key Data
| Aspect |
Data Point |
| Target Population (U.S.) |
~14,000 CF patients eligible |
| Prescriptions (2022) |
2,500-3,000 units/quarter |
| Market Share (2023) |
15-20% of CF therapy market |
| Launch Price (2015) |
~$259,000/year |
| Current Estimated Price |
$270,000–$275,000/year |
| Patent Expiry |
2024–2025 (primary) |
| Market Penetration |
Growing, but limited by competition and cost |
Key Takeaways
- Orkambi remains a significant therapy for CF, but faces increasing competition from newer, more comprehensive triple therapies.
- Price projections suggest marginal increases unless forced by patent expiry or market competition.
- The upcoming patent expirations may pave the way for generics, significantly impacting pricing.
- Market growth depends on expanded indications and diagnostic rates, especially in pediatric populations.
FAQs
1. How will patent expiry impact Orkambi’s price?
Patent expirations in 2024–2025 could lead to generic entry, causing substantial price reductions, potentially 50% or more.
2. What is the primary competitive threat to Orkambi?
Trikafta, approved in 2019, dominates the market with broader mutation coverage and improved efficacy.
3. Are biosimilars expected for Lumacaftor/Ivacaftor?
Biosimilar development depends on patent and exclusivity status; if allowed, biosimilars could compete within 3-5 years after patent expiry.
4. How does pricing compare internationally?
Prices in Europe and Canada are generally lower due to different healthcare systems, with discounts and negotiations translating into 20-40% lower prices compared to the U.S.
5. What factors influence future demand for Orkambi?
Expanded indications, increased diagnosis, and insurance reimbursements determine demand. Competition and pricing will also affect patient access.
References
[1] Food and Drug Administration (FDA). (2015). Orkambi approval letter.
[2] IQVIA. (2022). Pharmaceutical Market Data.
[3] Cystic Fibrosis Foundation. (2022). Patient Registry Report.
[4] EvaluatePharma. (2022). Market Intelligence and Price Trends.
[5] U.S. Patent and Trademark Office. (2023). Patent Status for Lumacaftor/Ivacaftor.
